| Identification | Back Directory | [Name]
LY 2140023 | [CAS]
635318-55-7 | [Synonyms]
LY2140023 monohydrate
PoMagluMetad Methionil
VOYCNOJFAJAILW-CAMHOICYSA-N
Pomaglumetad methionil anhydrous
2-Thiabicyclo[3.1.0]hexane-4,6-dicarboxylic acid, 4-[[(2S)-2-amino-4-(methylthio)-1-oxobutyl]amino]-, 2,2-dioxide, (1R,4S,5S,6S)- | [Molecular Formula]
C12H18N2O7S2 | [MDL Number]
MFCD32661884 | [MOL File]
635318-55-7.mol | [Molecular Weight]
366.41 |
| Chemical Properties | Back Directory | [Melting point ]
203 °C | [Boiling point ]
773.6±60.0 °C(Predicted) | [density ]
1?+-.0.1 g/cm3(Predicted) | [storage temp. ]
-20°C | [solubility ]
DMSO: 0.25mg/mL
dilute NaOH: 10mg/mL | [form ]
powder | [pka]
2.14±0.40(Predicted) | [color ]
white |
| Hazard Information | Back Directory | [Uses]
LY 2140023 is a drug developed as a treatment option for schizophrenia. It targets the mGlu2/3 receptor once metabolized. | [Biological Activity]
Primary Target
mGlu2 & mGlu3''Target Ki: 149 nM and 92 nM for human mGlu2 and mGlu3respectively. | [in vivo]
Pomaglumetad methionil (LY2140023; orally; 3-300 mg/kg; once daily for 7 days) dose-dependent increases the levels of the dopamine metabolites dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA)[1]. | Animal Model: | Male Fischer rats (approximately 250 g)[1] | | Dosage: | 3, 10, and 300 mg/kg | | Administration: | Orally; once daily for 7 days | | Result: | Dose-dependent increased the levels of the dopamine metabolites DOPAC and HVA.
|
| [IC 50]
mGluR2; mGluR3 |
|
| Company Name: |
NCE Biomedical Co.,Ltd.
|
| Tel: |
4000-027-021 |24 +86-13986109188 | +86-15623472865 | +81-08033611988 |
| Website: |
www.chemicalbook.com/ShowSupplierProductsList15748/0_EN.htm |
| Company Name: |
BOC Sciences
|
| Tel: |
|
| Website: |
https://www.bocsci.com |
| Company Name: |
cjbscvictory
|
| Tel: |
13348960310 |
| Website: |
https://www.weikeqi-biotech.com/ |
| Company Name: |
Merck KGaA
|
| Tel: |
21-20338288 |
| Website: |
www.sigmaaldrich.cn |
|